MedTrace Logo

Thalidomide Low Threshold in Epilepsy

NCT01061866 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2010-02-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether thalidomide is effective in the refractory epilepsy treatment.

Conditions

  • Refractory Epilepsy

Interventions

DRUG

3-phthalimidoglutarimide (Thalidomide)

Thalidomide at 200 mg dosage bid was administered during a twelve month period.

Sponsors & Collaborators

  • National Council of Science and Technology, Mexico

    collaborator OTHER

  • National Institute of Neurology and Neurosurgery, Mexico

    lead OTHER

Principal Investigators

  • Julio Sotelo, MD · National Institute of Neurology and Neurosurgery of Mexico

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-06-30
Completion
2008-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01061866 on ClinicalTrials.gov